Company profile · Solna, Sweden

Biosergen

Antifungal Drugs, Anti-Infectives, Invasive Fungal Infections, Clinical Development, and Biotech · Clinical-stage therapeutics platform

Verified 22 Mar 2026 · 2 sources

Clinical

Biosergen runs anti-infective drug development, clinical development, and biotech platform management in Solna, Sweden.

Contact & location
LinkedIn
Company page
Lead
Tine Kold Olesen (verified ↗)
Compliance
Not yet on record
Last reviewed
22 Mar 2026 (4mo ago)
Scale
Clinical-stage therapeutics platform
Capabilities
Anti-Infective Drug Development · Clinical Development · Biotech Platform Management
Founded
2006
Headcount
1-10
Editorial note

Antifungal Drugs, Anti-Infectives, Invasive Fungal Infections, Clinical Development, and Biotech

Biosergen is published because official company materials confirm current leadership, Solna operating address, and a real anti-infective therapeutics platform.

Editorial note

Biosergen is published because official company materials confirm current leadership, Solna operating address, and a real anti-infective therapeutics platform.

FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026Last reviewed: 22 March 2026

Verification details

Site and address
Clinical profileSTATUS: VERIFIED MARCH 2026

Tine Kold Olesen

Chief Executive Officer

Check official leadership source
Full addressFogdevreten 2, 17165 Solna, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source

Official Biosergen contact page listing the Solna address.

Open source
Operating profile

Clinical-stage therapeutics platform

Solna, Sweden. Antifungal Drugs, Anti-Infectives, Invasive Fungal Infections, Clinical Development, and Biotech. Review completed on 22 Mar 2026.

2026 technical specializationAntifungal Drugs, Anti-Infectives, Invasive Fungal Infections, Clinical Development, and Biotech
Core capabilities
Anti-Infective Drug DevelopmentClinical DevelopmentBiotech Platform Management
Governance

Swedish corporate and clinical-development oversight

Official leadership disclosure, Official Solna address disclosure, Therapeutics platform claim

Capabilities

Anti-Infective Drug Development
Clinical Development
Biotech Platform Management

Sources

The official sources used to verify this profile.

Leadership evidenceOfficial Biosergen contact page naming Tine Kold Olesen as Chief Executive Officer.Source origin: biosergen.netOpen source
Supporting evidenceOfficial Biosergen site describing the Solna antifungal-drug platform.Source origin: biosergen.netOpen source
Physical-site evidenceOfficial Biosergen contact page listing the Solna address.Source origin: biosergen.netOpen source

Infrastructure

Anti-infective R&D workflow
Clinical program infrastructure
Therapeutics platform systems

Certifications

GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.

GMP
REVIEW IN PROGRESS 2026
GLP
REVIEW IN PROGRESS 2026
ISO-13485
REVIEW IN PROGRESS 2026
FDA-Inspected
REVIEW IN PROGRESS 2026

Review log

22 Mar 2026: Executive identity confirmed via official management disclosure.
22 Mar 2026: Full trust review completed.

Frequently asked questions

Where is Biosergen located?
Biosergen operates from Fogdevreten 2, 17165 Solna, Sweden, Solna, Sweden.
Who runs Biosergen?
Biosergen is led by Tine Kold Olesen, Chief Executive Officer. Verified 22 Mar 2026.
What does Biosergen do?
Biosergen runs anti-infective drug development, clinical development, and biotech platform management in Solna, Sweden. Core capabilities: Anti-Infective Drug Development, Clinical Development, Biotech Platform Management.
Editorial context

Related technical briefs

Briefs that name Solna as a covered market or city.